Key Highlights
- HAO traded 10.89% lower at USD 1.75 in pre-market trading on November 3, 2026.
- No company announcement dated October 30 to November 3, 2026 was identified as a catalyst.
- The year ended June 30, 2026 recorded a net loss of USD 9.54 million, compared with Net Income of USD 3.88 million a year earlier.
- Cash and cash equivalents stood at USD 10,933,108 on June 30, 2026.
- The company priced a USD 4 million registered direct offering on July 10, 2026.
What moved the stock in pre-market trading (down USD 0.2139, 10.89%)
Haoxi Health Technology (NASDAQ:HAO) fell 10.89% to USD 1.75 in pre-market trading on November 3, 2026, compared with the November 2, 2026 close. Extended-hours Volume is thin, so prices can swing hard on small orders.
A search of company releases and regulatory filings dated October 30 to November 3, 2026 turned up no announcement explaining the move. It appears to be price action in a stock with a turbulent year behind it. Under USD 5, the shares are a penny stock, which brings higher volatility, thin Liquidity and dilution risk.
A year of share consolidations and financings
On May 11, 2026 the company announced a USD 6.5 million registered direct offering at USD 0.25 per share. A one-for-128 reverse share split was announced on May 19, 2026, and a one-for-20 consolidation followed on August 12, 2026.
At an extraordinary general meeting on June 2, 2026, shareholders were asked to approve consolidations at a cumulative ratio of up to one-for-8,000, with the stated goal of keeping the Class A shares above the Nasdaq minimum bid price of USD 1.00. On July 10, 2026 the company priced a registered direct offering of 10,000,000 Class A shares, or pre-funded warrants, at USD 0.40 per share for gross proceeds of about USD 4 million.
Business background and latest results
Haoxi Health Technology is a Beijing-based online Marketing provider. It helps advertisers, mainly in healthcare, reach customers through short-video and news-feed Advertising on major Chinese platforms.
According to its Annual Report filed on September 30, 2026, the company served 565 advertisers in the year ended June 30, 2026, of which 230 were healthcare companies. It posted a net loss of USD 9.54 million, including a USD 6.07 million credit-loss allowance and a USD 1.5 million Impairment of intangible assets. The prior year brought net income of USD 3.88 million on Revenue of USD 32.80 million, down 32% from USD 48.52 million.
Balance sheet and risks
Cash and cash equivalents were USD 10,933,108 at June 30, 2026, and net cash used in Operating Activities for the year was USD 2.57 million. Visible risks include further share issuance at low prices, repeated consolidations and customer Credit quality given the large allowance.
What to watch next
Investors will look for any 6-K filing that sets out new financing, a further consolidation or a Nasdaq compliance update. Until the company says otherwise, the pre-market move reads as price action without an identified catalyst.






Please wait processing your request...